Skip to main content
Clinical Trials/CTRI/2018/04/013279
CTRI/2018/04/013279
Active, not recruiting
Phase 4

A study to assess the efficacy of curcumin as an immunomodulator in Rheumatoid arthritis

Dr Padmanabha Shenoy D0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Dr Padmanabha Shenoy D
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Dr Padmanabha Shenoy D

Eligibility Criteria

Inclusion Criteria

  • Diagnosed cases of rheumatoid arthritis according to the 2010 ACR/EULAR classification criteria
  • On conventional DMARDs for at least last six months.
  • On sustained remission based on DAS 28 (DAS 28 \< 2\.6\) and SDAI ââ?°Â¤ 3\.3 and TJC (44\) \< 0 and SJC (44\) \< 0 for more than 6 months without requirement of corticosteroids or NSAIDs.
  • Documented remission status at a minimum of two consecutive visits during last 6 months .

Exclusion Criteria

  • Having other associated rheumatological diseases
  • Functional class IV
  • Abnormal liver function (defined as AST/ALT \> 3 X upper normal limit ) and active hepatits/cirrhosis
  • Abnormal renal function / chronic renal failure ( S. creatinine ââ?°Â¥ 2mg/dl)
  • Those who are currently on curcumin supplements
  • Known allergic reaction to curcumin
  • Major comorbidities like severe hypertension , uncontrolled diabetes mellitus , severe respiratory or cardiovascular disease , malignancy
  • Current or past use of biologics
  • Current use of Warfarin
  • Subjects with acute episodes of cholecystitis within last few months

Outcomes

Primary Outcomes

Not specified

Similar Trials